科微学术

生物工程学报

2025年5月29日 5:55 星期四
首页 > 过刊浏览>2023年第39卷第4期 >1290-1303. DOI:10.13345/j.cjb.220603
PDF HTML阅读 XML下载 导出引用 引用提醒
活体生物药的应用及在遗传性代谢缺陷病治疗中的展望
作者:
基金项目:

上海市卫生健康委员会青年基金(20204Y0273)


Application of live biotherapeutic products and perspective in the treatment of inherited metabolic disease
Author:
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [53]
    • |
  • 相似文献
    • | | |
  • 文章评论
    摘要:

    活体生物药(live biotherapeutic products, LBPs)是指来自于人体肠道内或自然界中能够治疗人类疾病的活性菌。但天然筛选的活菌存在治疗效果不明显、差异性较大等缺点，难以满足个性化诊疗的需要。近年来，随着合成生物学的发展，研究者利用生命科学及工程科学手段，设计并构建了若干可响应外界复杂环境信号的工程菌株，加快了活体生物药的研发和应用过程。遗传性代谢缺陷病(inherited metabolic disease)是因体内某些酶的遗传缺陷致使体内相应的代谢物不能正常代谢而引发一系列临床症状的一类疾病，因此利用合成生物学技术，针对特定缺陷的酶设计重组活体生物药，未来有希望用于遗传性代谢缺陷病的治疗。本综述以活体生物药为切入点，并结合国内外文献综述，来探讨活体生物药在疾病治疗中的应用，以及对遗传性代谢缺陷病治疗的潜力。

    Abstract:

    Live biotherapeutic products (LBPs) refer to the living bacteria derived from human body intestinal gut or in nature that can be used to treat the human disease. However, the naturally screened living bacteria have some disadvantages, such as deficient therapeutic effect and great divergence, which fall short of the personalized diagnosis and treatment needs. In recent years, with the development of synthetic biology, researchers have designed and constructed several engineered strains that can respond to external complex environmental signals, which speeded up the process of development and application of LBPs. Recombinant LBPs modified by gene editing can have therapeutic effect on specific diseases. Inherited metabolic disease is a type of disease that causes a series of clinical symptoms due to the genetic defect of some enzymes in the body, which may cause abnormal metabolism the corresponding metabolites. Therefore, the use of synthetic biology to design LBPs targeting specific defective enzymes will be promising for the treatment of inherited metabolic defects in the future. This review summarizes the clinic applications of LBPs and its potential for the treatment of inherited metabolic defects.

    参考文献
    [1] KINROSS JM, DARZI AW, NICHOLSON JK. Gut microbiome-host interactions in health and disease[J]. Genome Medicine, 2011, 3(3):14.
    [2] CHO I, BLASER MJ. The human microbiome:at the interface of health and disease[J]. Nature Reviews Genetics, 2012, 13(4):260-270.
    [3] HERTEL J, FÄSSLER D, HEINKEN A, WEIß FU, RÜHLEMANN M, BANG C, FRANKE A, BUDDE K, HENNING AK, PETERSMANN A, VÖLKER U, VÖLZKE H, THIELE I, GRABE HJ, LERCH MM, NAUCK M, FRIEDRICH N, FROST F. NMR metabolomics reveal urine markers of microbiome diversity and identify benzoate metabolism as a mediator between high microbial alpha diversity and metabolic health[J]. Metabolites, 2022, 12(4):308.
    [4] RUSSO GI, BONGIORNO D, BONOMO C, MUSSO N, STEFANI S, SOKOLAKIS I, HATZICHRISTODOLOU G, FALCONE M, CAI T, SMARRAZZO F, VERZE P. The relationship between the gut microbiota, benign prostatic hyperplasia, and erectile dysfunction[J]. International Journal of Impotence Research, 2022:Online ahead of print.
    [5] SUN X, FIALA JL, LOWERY D. Patent watch:modulating the human microbiome with live biotherapeutic products:intellectual property landscape[J]. Nature Review Drug Discovery, 2016, 15(4):224-225.
    [6] HILL C, GUARNER F, REID G, GIBSON GR, MERENSTEIN DJ, POT B, MORELLI L, CANANI RB, FLINT HJ, SALMINEN S, CALDER PC, SANDERS ME. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nature Review Gastroenterol Hepatol, 2014, 11(8):506-514.
    [7] 徐晴, 李若铭, 王桂芹. 益生菌对鱼类黏膜免疫影响的研究进展[J]. 饲料工业, 2022, 43(6):5-8. XU Q, LI RM, WANG GQ. Research progress of the effect of probiotics on mucosal immunity of fish[J]. Feed Industry, 2022, 43(6):5-8(in Chinese).
    [8] 周敏, 汪凯歌, 张濂, 马曦. 微生物-肠-肌轴调节骨骼肌代谢和功能的研究进展[J]. 畜牧兽医学报, 2022, 53(9):2845-2857. ZHOU M, WANG KG, ZHANG L, MA X. Advances in microbiota-gut-muscle axis regulating skeletal muscle metabolism and function[J]. Acta Veterinariaet Zootechnica Sinica, 2022, 53(9):2845-2857(in Chinese).
    [9] O'TOOLE PW, MARCHESI JR, HILL C. Next- generation probiotics:the spectrum from probiotics to live biotherapeutics[J]. Nature Microbiology, 2017, 2:1-6.
    [10] 赵云飞, 祝莎莎, 黄新文. 异戊酸血症的研究进展[J]. 中华医学遗传学杂志, 2022, 39(1):99-102. ZHAO YF, ZHU SS, HUANG XW. Current understanding and progress of research on isovaleric academia[J]. Chinese Journal of Medical Genetics, 2022, 39(1):99-102(in Chinese).
    [11] Early Clinical Trials with Live Biotherapeutic Products:Chemistry, Manufacturing, and Control Information[EB/OL].[2022-10-20]. Early Clinical Trials with Live Biotherapeutic Products:Chemistry, Manufacturing, and Control Information; Guidance for Industry (fda.gov).
    [12] 王蕾, 梁自超, 孙瑞涛. 活菌制剂作为反刍动物添加剂的应用进展[J]. 中国奶牛, 2018(3):9-13. WANG L, LIANG ZC, SUN RT. The application of living bacteria preparation as a ruminant feed additive[J]. China Dairy Cattle, 2018(3):9-13(in Chinese).
    [13] 智发朝, 王晔, 刘洋洋, 李平, 梁德宝.. 国际活菌药物研究现状及展望[J]. 现代消化及介入诊疗, 2019, 24(2):109- 113, 104. ZHI F(C/Z), WANG Y, LIU YY, LI P, LIANG DB. Present situation and prospect of international research on live bacteria drugs[J]. Modern Digestion & Intervention, 2019, 24(2):109-113, 104(in Chinese).
    [14] 高倩, 张宏翔, 江洪, 叶茂. 全球微生态药物研发现状及发展趋势[J]. 中国生物工程杂志, 2020, 40(S1):166-173. GAO Q, ZHANG HX, JIANG H, YE M. Current status and trend of R & D of microecological drugs[J]. China Biotechnology, 2020, 40(S1):166-173(in Chinese).
    [15] GARBER K. First microbiome-based drug clears phase III, in clinical trial turnaround[J]. Nature Reviews Drug Discovery, 2020, 19(10):655-656.
    [16] DUCARMON QR, KUIJPER EJ, OLLE B. Opportunities and challenges in development of live biotherapeutic products to fight infections[J]. The Journal of Infectious Diseases, 2021, 223(Supplement_3):S283-S289.
    [17] RUDICK CN, TAYLOR AK, YAGGIE RE, SCHAEFFER AJ, KLUMPP DJ. Asymptomatic bacteriuria Escherichia coli are live biotherapeutics for UTI[J]. PLoS One, 2014, 9(11):e109321.
    [18] SEGEV G, SYKES JE, KLUMPP DJ, SCHAEFFER AJ, ANTAKI EM, BYRNE BA, YAGGIE RE, WESTROPP JL. Evaluation of the live biotherapeutic product, asymptomatic bacteriuria Escherichia coli 2-12, in healthy dogs and dogs with clinical recurrent UTI[J]. Journal of Veterinary Internal Medicine, 2018, 32(1):267-273.
    [19] DAUSSET C, PATRIER S, GAJER P, THORAL C, LENGLET Y, CARDOT JM, JUDLIN P, RAVEL J, NIVOLIEZ A. Comparative phase I randomized open-label pilot clinical trial of Gynophilus®(Lcr regenerans®) immediate release capsules versus slow release muco-adhesive tablets[J]. European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37(10):1869-1880.
    [20] BAUTISTA CT, WURAPA E, SATEREN WB, MORRIS S, HOLLINGSWORTH B, SANCHEZ JL. Bacterial vaginosis:a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections[J]. Military Medical Research, 2016, 3:4.
    [21] SOBEL JD, FARO S, FORCE RW, FOXMAN B, LEDGER WJ, NYIRJESY PR, REED BD, SUMMERS PR. Vulvovaginal candidiasis:epidemiologic, diagnostic, and therapeutic considerations[J]. American Journal of Obstetrics and Gynecology, 1998, 178(2):203-211.
    [22] KHANNA S, PARDI DS, JONES C, SHANNON WD, GONZALEZ C, BLOUNT K. RBX7455, a non-frozen, orally administered investigational live biotherapeutic, is safe, effective, and shifts patients' microbiomes in a phase 1 study for recurrent Clostridioides difficile infections[J]. Clinical Infectious Diseases:an Official Publication of the Infectious Diseases Society of America, 2021, 73(7):e1613-e1620.
    [23] OKA A, SARTOR RB. Microbial-based and microbial-targeted therapies for inflammatory bowel diseases[J]. Digestive Diseases and Sciences, 2020, 65(3):757-788.
    [24] LORENTE-PICÓN M, LAGUNA A. New avenues for Parkinson's disease therapeutics:disease-modifying strategies based on the gut microbiota[J]. Biomolecules, 2021, 11(3):433.
    [25] COOK DP, GYSEMANS C, MATHIEU C. Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy[J]. Frontiers in Immunology, 2018, 8:1961.
    [26] CHEN ZY, GUO LL, ZHANG YQ, WALZEM RL, PENDERGAST JS, PRINTZ RL, MORRIS LC, MATAFONOVA E, STIEN X, KANG L, COULON D, MCGUINNESS OP, NISWENDER KD, DAVIES SS. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity[J]. Journal of Clinical Investigation, 2014, 124(8):3391-3406.
    [27] LEE J, KEATES AC, LI CJ. Synthetic biology medicine and bacteria-based cancer therapeutics[J]. Methods in Molecular Biology:Clifton, N J, 2021, 2323:267-280.
    [28] BAO YW, CHENG Y, LIU W, LUO W, ZHOU P, QIAN D. Bacteria-based synergistic therapy in the backdrop of synthetic biology[J]. Frontiers in Oncology, 2022, 12:845346.
    [29] SEGERS ME, LEBEER S. Towards a better understanding of Lactobacillus rhamnosus GG:host interactions[J]. Microbial Cell Factories, 2014, 13(Suppl 1):S7.
    [30] ROUANET A, BOLCA S, BRU A, CLAES I, CVEJIC H, GIRGIS H, HARPER A, LAVERGNE SN, MATHYS S, PANE M, POT B, SHORTT C, ALKEMA W, BEZULOWSKY C, BLANQUET-DIOT S, CHASSARD C, CLAUS SP, HADIDA B, HEMMINGSEN C, JEUNE C, et al. Live biotherapeutic products, a road map for safety assessment[J]. Frontiers in Medicine, 2020, 7:237.
    [31] BRENTON DP, ISENBERG DA, CUSWORTH DC, GARROD P, KRYWAWYCH S, STAMP TC. The adult presenting idiopathic Fanconi syndrome[J]. Journal of Inherited Metabolic Disease, 1981, 4(4):211-215.
    [32] 宋力. 遗传性代谢缺陷病研究进展[J]. 中国优生与遗传杂志, 2003, 2:7-8. SONG L. Advances in hereditary metabolic defects[J]. Chinese Journal of Birth Health & Heredity, 2003, 2:7-8(in Chinese).
    [33] BEAUDET AL, SCRIVER CR, SLY WS, VALLE D. Genetics, biochemistry, and molecular basis of variant human phenotypes[M]. The Online Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY; McGraw-Hill Education, 1995:53-118.
    [34] ZUDENIGO D, RELJA M. Hepatolenticular degeneration[J]. Neurologija, 1990, 39(2):115-127.
    [35] KRUSZKA P, REGIER D. Inborn errors of metabolism:from preconception to adulthood[J]. American Family Physician, 2019, 99(1):25-32.
    [36] 方俊敏, 王慕逖. 遗传性代谢缺陷病的诊断[J]. 中华儿科杂志, 2001, 39(3):176-179. FANG JM, WANG MT. Diagnosis of hereditary metabolic defects[J]. Chinexe Journal of Pediatrics, 2001, 39(3):176-179. (in Chinese)
    [37] 陈玉兰. 全外显子测序技术在新生儿危重症遗传病诊断中的应用研究[D]. 广州:广州医科大学硕士学位论文, 2021. CHEN YL. Detection of inherited diseases in critically ill neonates using whole exome sequencing technology[D]. Guangzhou:Master's Thesis of Guangzhou Medical University, 2021(in Chinese).
    [38] 陈梅, 李惠娟, 李毅. 胎儿超声检查辅助遗传病产前诊断的研究进展[J]. 泰山医学院学报, 2020, 41(7):552-555. CHEN M, LI HJ, LI Y. Research progress of prenatal diagnosis of genetic diseases assisted by fetal ultrasound examination[J]. Journal of Taishan Medical College, 2020, 41(7):552-555(in Chinese).
    [39] 刘晓丽, 钟青燕, 罗世强, 王秋华, 许泽辉, 覃柳群, 王敬仁, 陈丽竹, 唐宁. 特异性短串联重复序列位点检测在遗传病产前诊断中的应用[J]. 广西医学, 2020, 42(23):3050-3053, 3067. LIU XL, ZHONG QY, LUO SQ, WANG QH, XU ZH, QIN LQ, WANG JR, CHEN LZ, TANG N. Application of specific short tandem repeats locus detection in prenatal diagnosis of genetic diseases[J]. Guangxi Medical Journal, 2020, 42(23):3050-3053, 3067(in Chinese).
    [40] 李博文, 梁世倩, 白健, 秦鸿雁. CRISPR-dCas9转录调控系统及其在遗传病治疗研究中的应用[J]. 生命科学, 2019, 31(6):628-636. LI BW, LIANG SQ, BAI J, QIN HY. The CRISPR-dCas9 system regulating genomic transcription and its application in genetic disease therapy[J]. Chinese Bulletin of Life Sciences, 2019, 31(6):628-636(in Chinese).
    [41] HURT SC, DICKSON PI, CURIEL DT. Mucopolysaccharidoses type I gene therapy[J]. Journal of Inherited Metabolic Disease, 2021, 44(5):1088-1098.
    [42] BRYSON TE, ANGLIN CM, BRIDGES PH, et al. Nuclease-mediated gene therapies for inherited metabolic diseases of the liver[J]. The Yale Journal of Biology and Medicine, 2017, 90(4):553-566.
    [43] YILMAZ BS, GURUNG S, PEROCHEAU D, COTTLE RN. Gene therapy for inherited metabolic diseases[J]. Journal of Mother and Child, 2020, 24(2):53-64.
    [44] CUBILLOS-RUIZ A, GUO TX, SOKOLOVSKA A, MILLER PF, COLLINS JJ, LU TK, LORA JM. Engineering living therapeutics with synthetic biology[J]. Nature Reviews Drug Discovery, 2021, 20(12):941-960.
    [45] CABLE J, LEONARD JN, LU TK, XIE Z, CHANG MW, FERNÁNDEZ L, LORA JM, KAUFMAN HL, QUINTANA FJ, GEIGER R, LESSER CF, LYNCH JP, HAVA DL, CORNISH VW, LEE GK, DIANDRETH B, FERO M, SRIVASTAVA R, de COSTER T, ROYBAL KT, et al. Synthetic biology:at the crossroads of genetic engineering and human therapeutics-a keystone symposia report[J]. Annals of the New York Academy of Sciences, 2021, 1506(1):98-117.
    [46] PUURUNEN MK, VOCKLEY J, SEARLE SL, SACHAROW SJ, PHILLIPS JA, DENNEY WS, GOODLETT BD, WAGNER DA, BLANKSTEIN L, CASTILLO MJ, CHARBONNEAU MR, ISABELLA VM, SETHURAMAN VV, RIESE RJ, KURTZ CB, BRENNAN AM. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria:a first-in-human phase 1/2a study[J]. Nature Metabolism, 2021, 3(8):1125-1132.
    [47] ISABELLA VM, HA BN, CASTILLO MJ, LUBKOWICZ DJ, ROWE SE, MILLET YA, ANDERSON CL, LI N, FISHER AB, WEST KA, REEDER PJ, MOMIN MM, BERGERON CG, GUILMAIN SE, MILLER PF, KURTZ CB, FALB D. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria[J]. Nature Biotechnology, 2018, 36(9):857-864.
    [48] KNIGHT J, DEORA R, ASSIMOS DG, HOLMES RP. The genetic composition of Oxalobacter formigenes and its relationship to colonization and calcium oxalate stone disease[J]. Urolithiasis, 2013, 41(3):187-196.
    [49] LUBKOWICZ D, HORVATH NG, JAMES MJ, CANTARELLA P, RENAUD L, BERGERON CG, SHMUELI RB, ANDERSON C, GAO JR, KURTZ CB, PERREAULT M, CHARBONNEAU MR, ISABELLA VM, HAVA DL. An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria[J]. Molecular Systems Biology, 2022, 18(3):e10539.
    [50] OZDEMIR T, FEDOREC AJH, DANINO T, BARNES CP. Synthetic biology and engineered live biotherapeutics:toward increasing system complexity[J]. Cell Systems, 2018, 7(1):5-16.
    [51] YAMAMOTO S, JUN WD, KATAYAMA T, JIKIMOTO T, NAKAMURA M, KINOSHITA S, LEE KM, KAWABATA M, SHIRAKAWA T. Genetically modified Bifidobacterium displaying Salmonella- antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model[J]. Vaccine, 2010, 28(41):6684-6691.
    [52] DONG Y, XU T, XIAO G, HU Z, CHEN J. Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease[J]. Frontiers in Bioengineering and Biotechnology, 2022, 10:909591.
    [53] WRIGHT O, DELMANS M, STAN GB, ELLIS T. GeneGuard:a modular plasmid system designed for biosafety[J]. ACS Synthetic Biology, 2015, 4(3):307-316.
    相似文献
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

陈钊炜,郭敏,郑华军. 活体生物药的应用及在遗传性代谢缺陷病治疗中的展望[J]. 生物工程学报, 2023, 39(4): 1290-1303

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2022-07-31
  • 录用日期:2022-10-31
  • 在线发布日期: 2023-04-14
  • 出版日期: 2023-04-25
文章二维码
您是第6445348位访问者
生物工程学报 ® 2025 版权所有

通信地址：中国科学院微生物研究所    邮编：100101

电话：010-64807509   E-mail：cjb@im.ac.cn

技术支持：北京勤云科技发展有限公司